We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+5.69%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$1.68B
AUM Growth
-$109M
Cap. Flow
-$13.5M
Cap. Flow %
-0.8%
Top 10 Hldgs %
48.34%
Holding
155
New
26
Increased
23
Reduced
13
Closed
37

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$26.4M
2
VTYX
Ventyx Biosciences
VTYX
+$20.8M
3
CBIO
Crescent Biopharma
CBIO
+$19.3M
4
APLS
Apellis Pharmaceuticals
APLS
+$18.3M
5
VRDN icon
Viridian Therapeutics
VRDN
+$16.2M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$30.4M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$28.4M
3
ONC
BeOne Medicines Ltd
ONC
+$23.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$21.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 93.97%
2 Consumer Discretionary 5.18%
3 Financials 0.37%
4 Real Estate 0.31%
5 Technology 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FUSN
51
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$7.45M 0.44%
1,975,000
+1,225,000
+163% +$4.82M
RPTX
52
DELISTED
Repare Therapeutics
RPTX
$6.89M 0.41%
700,000
– –
RNAC icon
53
Cartesian Therapeutics
RNAC
$239M
$6.79M 0.4%
162,773
– –
PLRX icon
54
Pliant Therapeutics
PLRX
$69.4M
$6.79M 0.4%
+255,085
New +$7.26M
OVID icon
55
Ovid Therapeutics
OVID
$529M
$6.45M 0.38%
2,500,000
– –
AMAM
56
DELISTED
Ambrx Biopharma Inc
AMAM
$6.26M 0.37%
702,291
-1,450,000
-67% -$7.29M
DYN icon
57
Dyne Therapeutics
DYN
$3.34B
$6.14M 0.36%
532,609
+7,609
+1% +$98.8K
KDNY
58
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$5.99M 0.36%
+258,687
New +$6.17M
ITOS
59
DELISTED
iTeos Therapeutics
ITOS
$5.44M 0.32%
400,000
– –
IMA
60
ImageneBio Inc
IMA
$55.8M
$5.35M 0.32%
129,126
– –
BEKE icon
61
KE Holdings
BEKE
$17.9B
$5.18M 0.31%
275,000
-225,000
-45% -$4.17M
VKTX icon
62
Viking Therapeutics
VKTX
$3.49B
$5M 0.3%
+300,000
New +$3.1M
ROIV icon
63
Roivant Sciences
ROIV
$28.5B
$4.43M 0.26%
+600,000
New +$4.94M
VERV
64
DELISTED
Verve Therapeutics
VERV
$4.33M 0.26%
300,000
– –
SLDB icon
65
Solid Biosciences
SLDB
$897M
$4.31M 0.26%
909,219
– –
SYRS
66
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.94M 0.23%
1,475,744
+11,915
+0.8% +$46.2K
ANNX icon
67
Annexon
ANNX
$743M
$3.92M 0.23%
+1,018,303
New +$5.6M
PFTA
68
DELISTED
Perception Capital Corp. III Class A Ordinary Share
PFTA
$3.89M 0.23%
380,000
– –
GOSS icon
69
Gossamer Bio
GOSS
$63.4M
$3.81M 0.23%
37,852
-2,731
-7% -$418K
NBTX
70
Nanobiotix
NBTX
$1.79B
$3.52M 0.21%
1,000,000
– –
SLN
71
Silence Therapeutics
SLN
$774M
$3.13M 0.19%
+505,074
New +$5.96M
BDTX icon
72
Black Diamond Therapeutics
BDTX
$113M
$3.11M 0.18%
1,646,517
– –
BMRN icon
73
BioMarin Pharmaceuticals
BMRN
$12.5B
$3.11M 0.18%
+31,967
New +$3.31M
NBP
74
NovaBridge Biosciences American Depositary Shares
NBP
$184M
$2.94M 0.17%
850,000
– –
TSM icon
75
TSMC
TSM
$2.15T
$2.79M 0.17%
+30,000
New +$2.69M
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2023 Portfolio in Review

As of Q1 2023, Artal Group held 155 positions worth $1.68B, down 6.1% from $1.79B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group's Q1 2023 filing shows 26 new, 23 increased, 13 reduced and 37 closed positions. Its largest new stake was Ventyx Biosciences: 535,812 shares worth $17.9M. The largest sale was BELLUS Health Inc., an estimated $30.4M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q1 2023 buy was Ventyx Biosciences: 535,812 shares worth $17.9M.
  • Artal Group added most to Revolution Medicines in Q1 2023, an estimated $26.4M increase.
  • Artal Group's biggest Q1 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $28.4M.
  • Artal Group fully exited BELLUS Health Inc. in Q1 2023, selling an estimated $30.4M.
  • Artal Group's ten largest holdings make up 48% of its $1.68B portfolio in Q1 2023.
  • Artal Group opened 26 new positions and closed 37 in Q1 2023.
  • Artal Group's portfolio value fell 6.1% quarter-over-quarter to $1.68B.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.